|This article is an orphan, as no other articles link to it. Please introduce links to this page from ; try the Find links tool for suggestions. (December 2008)|
4EGI-1 is a synthetic, biological molecule, which has been found to interfere with the growth of certain types of cancer cells. Its mechanism of action interrupts the binding of cellular initiation factor proteins involved in the translation of transcribed mRNA at the ribosome. The inhibition of these initiation factors prevents the initiation and translation of many proteins whose functions are essential to the rapid growth and proliferation of cancer cells.
4EGI-1 mimics the action of a class of cellular regulatory molecules that naturally inhibit the binding of two initiation factors necessary for interaction of transcribed mRNA with the subunits of ribosomal complexes. These naturally occurring regulatory molecules, or binding proteins (BPs), as a class known as 4E-BPs, bind to eukaryotic initiation factor (eIF) eIF4E, preventing its association with eIF4G, another initiation factor. These two proteins, under unregulated conditions, form a complex, known as eIF4F, which associates with the 5’ cap of mRNA and the ribosomal subunits. 4E-BPs, as small polypeptides, consist of the same amino acid sequence as the portion of eIF4G that interacts with eIF4E. 4EGI-1 thus prevents the proper association of mRNA, carrying the coded message of transcribed genes, with the ribosome, the cellular component necessary for the translation of those genes into functional proteins. Naturally occurring 4E-BPs are regulated by a protein kinase, mTOR, which through phosphorylation deactivates the binding affinity of 4E-BPs for the eIF4E protein. 1
Binding Site Specifics and Effects of Use
4EGI-1, like 4E-BP polypeptides, displaces eIF4G by associating with a binding site on E. Not only does the synthetic molecule prevent the association between the two initiation factors, but by binding to a different portion of E via the same motif, it has been shown to actually increase the binding affinity of E for endogenous (originating within an organism) 4E-BP1.1 The Harvard research group leading the study screened 16,000 compounds, looking for one that would displace a fluorescein-labeled peptide derived from the G sequence that binds to the E form at the same site. Eventually they turned up 4EGI-1, which displaced eIF4G by binding to a smaller subset of its binding site (on E). The newly found molecule had the added advantage of enhancing 4E-BP1 binding, a surprise given that this molecule is also believed to bind eIF4E via the same motif. It appears that by displacing the G sequence without blocking the entire binding interface of E, 4EGI-1 is able to clear the “docking site” of the endogenous regulator.
CAP Dependent vs. Initiation Factor Independent Translation
One caveat to the function of 4EGI-1 and thus the entire class of 4E-BP regulatory proteins is that both the synthetic and naturally occurring molecules are effective at inhibiting only cap-dependent translation, not initiation factor independent translation.
Messenger RNAs (mRNAs) are transcribed from DNA, and serve as templates for the synthesis of proteins by ribosomal translation. Weak mRNAs contain long and highly structured untranslatable regions at their 5’ end. This lengthy region makes it difficult for enzymes to determine where transcription should begin. As a result, initiation factor proteins are required for translation of the message into protein. These weak mRNAs, or mRNAs that carry the code for proteins involved in the development of cancer cells, require cap-dependent translation which necessitates the cellular involvement of the eIFs. Examples of weak mRNAs include those that code for proliferation-related, and anti-apoptotic proteins. Strong mRNAs, in contrast, are translated with much less cellular machinery such as eIFs and generally code for biologically necessary proteins, such as those needed for the essential metabolic processes of a cell. Therapies such as the use of 4EGI-1 against cancer cells can thus be created such that their biologic targets include only the initiation factors involved in the production of weak mRNA’s.
Cap-dependent translation involves a series of steps that join the small and large ribosomal subunits at the start codon of mRNA. The initiation factor complex eIF4F is dependent upon the presence of a 5’ mRNA cap upstream from the start codon in order to initiate translation.4
Initiation factor independent translation does not require the association of initiation factors with the 5’ cap of mRNA. As an alternative, the associated ribosomal units are moved to the start location by Internal Ribosome Entry Site trans acting factors (ITAF)s. It has been found that several cellular proteins that respond to apoptotic signals are translated in this fashion.5
The Techniques of Discovery
When attempting to identify biological molecules that would disrupt the formation of the F complex, researchers developed a high-throughput fluorescence polarization (FP)-binding assay. In this assay, a small peptide of a known sequence was synthesized and tagged with a fluorescent molecule. This traceable peptide of sequence KYTYDELFQLK binds to the binding site of endogenous 4E-BPs on eIF4E. 16,000 compounds of known chemical composition were then tested in this assay. Compounds that displace the labeled peptide from eIF4E would yield a decrease in fluorescence polarization. The sequence of 4EGI-1 was such that it displaced the labeled peptide, thus demonstrating its affinity for the complex binding site on E 2.
The Medical Potential of 4EGI-1
According to Gerhard Wagner, head of the Harvard research group that developed the molecule, the use of 4EGI-1 induced apoptosis in Jurkat Leukemia cells as well as inhibited the proliferation of type A549 lung cancer cells. However, the potency of the drug proved generally ineffective.The function of 4EGI-1 needs further researches.Researchers remain optimistic that the techniques developed during the discovery of 4EGI-1, such as the high-throughput fluorescence polarization (FP)-binding assay, will ultimately help with the discovery of new drugs.1
1Interlandi, Geneen. Focus Magazine. Harvard University. Feb. 9, 2007. <http://focus.hms.harvard.edu /2007/020907/biochemistry.shtml>.
2Moerke NJ, et al. Cell. 2007 Jan 26;128(2):257-67.
3Wilson, Alia. (2007): “Researchers Identify Method to Block Cancer”. City on a Hill Press. Volume 14, Issue 15.http://cityonahillpress.com/article.php?id=353
5Wikipedia: Eukaryotic Translation